Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company whose product development and regulatory compliance activities necessitate animal testing. The company manufactures medical devices, diagnostic systems, and laboratory supplies that are subject to regulatory approval processes requiring animal data. BD's own policy acknowledges this use, stating its commitment to the ethical treatment of animals "involved in biomedical research to advance human and veterinary patient health."

The company's products and research tools are directly cited in contemporary animal studies. For example, a 2025 study on opioid therapy published in *Pain* utilized BD syringes and catheters for procedures on mice and pigs. BD's culture media and collection tubes (e.g., BBL™, Difco™, K3-EDTA tubes) are standard supplies referenced in animal research across numerous scientific publications, indicating the company's embedded role in the research ecosystem.

While BD publishes a policy on the humane care and use of animals and extends its supplier expectations to third parties conducting animal testing on its behalf, the company's core business of developing and selling medical devices and diagnostics inherently relies on animal testing to meet global regulatory requirements for safety and efficacy.